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Abstract
Background: Recent electroconvulsive therapy (ECT) efficacy studies of right unilateral (RUL)
ECT may not apply to real life clinics with a wide range of patients with major depressive episodes.
Methods: The study included two groups of patients. In addition to a homogeneous group of
patients with major depression according to DSM-IV criteria with severity of the major depressive
episode > 16 scores on 17-item Hamilton Rating Scale for Depression (HDRS) (Group 1, n = 16),
we included a heterogeneous group of patients with less severe major depressive episodes or with
a variety of comorbid conditions (Group 2, n = 24). We randomly assigned the patients to an RUL
ECT treatment dosed at 5 or 2.5 times seizure threshold with an intent-to-treat design. The
outcomes measured blindly were HDRS, number of treatments, and Mini-Mental State Examination
(MMSE). The patients were considered to have responded to treatment if the improvement in
HDRS score was at least 60% and they had a total score of less than ten.
Results: The Group 2 patients responded poorer (8% vs. 63%), and had more often simultaneous
worsening in their MMSE scores than Group 1 patients. The differences in the outcomes between
the two different doses of RUL ECT treatment were not statistically significant.
Conclusions: ECT effectiveness seems to be lower in real-life heterogeneous patient groups than
in homogeneous patient samples used in experimental efficacy trials.
Background
A routine use of right unilateral (RUL) electroconvulsive
therapy (ECT) with an adequately suprathreshold stimu-
lus dose is encouraged by the latest recommendation of
the American Psychiatric Association (APA) Task Force
Guidelines for ECT [1]. RUL ECT at a moderate dose
(100–200%) above seizure threshold (ST) has been often
used as the initial standard treatment based on the previ-
ous recommendations [2,3]. More recently, high-dose
RUL ECT has been shown to be more effective than mod-
erate dose RUL ECT in the treatment of patients with ma-
jor depression [4,5]. The external validity of these studies,
however, is compromised by exclusion of depressive pa-
tients who are treated with ECT in real-world ECT practice,
i.e. patients with a lower severity of major depression or a
variety of co-morbid conditions [4,5], or patients with ex-
tremely severe illness [4]. Patients vary considerably in the
extent and severity of their cognitive side effects following
ECT. Available information about the factors that contrib-
ute to the individual differences is limited [1]. Thus, there
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is a lack of effectiveness information for a wide range of
depressive patients treated with the usual RUL ECT prac-
tice.
To clarify ECT effectiveness in a pragmatic heterogeneous
patient population, we included in our study, in addition
to patients with at least a moderate to severe major depres-
sive episode (Group 1), also depressive patients who
would have been excluded from recent efficacy studies
(Group 2). The latter group included patients with mild
depression and patients with comorbid conditions irre-
spective of the severity of depression. This study aimed to
compare the effect of RUL ECT in the two depression
groups, and also the effect of two different doses of RUL
ECT (high and moderate doses) on the outcome of treat-
ment in depressive patients separately in Groups 1 and 2.
Methods
Patients
The study patients gave their informed consent to the
study. They had been hospitalized at the Lapinlahti Hos-
pital of the Department of Psychiatry of Helsinki Univer-
sity Central Hospital because of a current major
depressive episode (DSM-IV)[6]. In addition, they had
not received ECT during the preceding 3-months period,
and their antidepressant medication was discontinued
(the minimum wash-out period was 5 days). For an anti-
depressant trial to be considered adequate, the threshold
for sufficient duration was a minimum of 4 weeks at or
above the threshold for the usual dosages of antidepres-
sants [7]. The major depressive episode diagnosis was
confirmed by P.H. by a semi-structured clinical interview
in which the collection of psychiatric history included a
symptom checklist for criteria of major depressive epi-
sode.
Sixty-one of the 81 patients referred to us and screened be-
tween October 1995 and February 1997 were treated with
ECT. Forty of the 61 (66%) patients were recruited for the
study. Of the 20 patients who did not have ECT, 11 pa-
tients did not have a current major depressive episode,
eight patients refused to have ECT, and one patient pre-
ferred to continue with antidepressant medication. Of
those 21 ECT patients who were rejected, one patient did
not give her consent to the study, eight patients received
bifrontal (BF) ECT as a part of a preliminary study com-
paring the effects of BF and RUL ECT, five patients partic-
ipated in the ongoing magnetoencephalography ECT
study, two patients refused to discontinue the antidepres-
sant medication, three patient received outpatient ECT,
one patient received bitemporal (BT) ECT for schizophre-
nia, and one patient BT ECT for catatonia. The mean (SD)
age (years) or gender (female/male) was not different be-
tween the rejected patients (n = 21) and the study patients
(n = 40) (47.7 ± 12.4 vs. 53.0 ± 11.0, t =1.70, df = 59, P =
0.095; 15/6 vs. 25/15, P = 0.58, respectively). Seven of the
21 rejected patients received RUL ECT for depression.
Only one of those patients met the above mentioned in-
clusion criteria but she refused to give her informed con-
sent to the present study.
The severity of the major depressive episode had to be >
16 points on the 17-item Hamilton Depression Rating
Scale (HDRS) [8] and there had to be no co-morbidity for
inclusion in Group 1. For inclusion in Group 2 the pa-
tients had to have a less severe major depressive episode
(HDRS ≤  16), or a history of alcohol abuse during the pre-
vious year, a history of schizophrenia, schizoaffective dis-
order or another psychotic disorder which was not part of
the mood disorder, a history of rapid-cycling bipolar ill-
ness (i.e., the occurrence of four or more mood episodes
during the previous 12 months), a history of neurological
illness, or a history of severe medical illness. All psychiat-
ric diagnoses were defined according to DSM-IV. The
study protocol was approved by the Ethics Committee of
the Department of Psychiatry of Helsinki University Cen-
tral Hospital according to the principles of the Helsinki
declaration.
Group 1 included 16 patients, and Group 2 24 patients. In
Group 2, four patients had had a mild major depressive
episode, eight patients had a history of alcohol abuse dur-
ing the previous year, two patients had a history of
schizoaffective disorders, four patients had a history of
psychotic disorder not otherwise specified, two patients
had a history of a neurological illness (one patient had
cerebellar ataxia, and the other ischemic cerebrovascular
disease) and four patients had a history of a severe medi-
cal illness (three patients had hypertensive cardiovascular
disease with concomitant risk factors: one had an aortic
homograft, one a history of epilepsy, and one a risk for es-
ophageal reflux, and one patient had coronary artery dis-
ease with coronary artery bypass grafting).
ECT
The patients were oxygenated (100% O2), and their cardi-
ovascular function was monitored using a Cardiocap™ II
anaesthesia monitor (Datex-Ohmeda, Helsinki, Finland).
d'Elia ECT stimulus placement [9], and the same brief-
pulse ECT device (THYMATRON-DGx™, Somatics Inc.,
Lake Bluff, IL, U.S.A) was used for all the patients. The
doses (median, range) for medications in i.v. anesthesia
were atropine (mg) (0.4, 0.4–0.7), methohexital (mg/kg)
(0.88, 0.69–1.26), and succinylcholine (mg/kg) (0.51,
0.39–0.71). There were no statistically significant differ-
ences (p > 0.05, Mann-Whitney U test) in the doses of
medications between the depression groups, or the ECT
groups.BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/2
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The ST level was measured at the first ECT treatment ses-
sion using a modified dose titration method [10]. ST was
determined by repeating the stimulus (1.0 ms pulse
width) at about 30 s intervals with stepwise increased
stimulus doses (25.2, 50.4, 75.6, and 100.8 mC). The ST
was defined as the ECT stimulus dose, which elicited a
generalized convulsive activity lasting visually for at least
25 s. Ictal EEG was monitored with standard THYMA-
TRON electrodes.
ECT was administered 3 times per week by two ECT psy-
chiatrists. In the second and subsequent treatments, the
stimulus was dosed either at five times the initial ST level
(400% above the ST level, RUL 5) or at 2.5 times the ST
level (150% above the ST level, RUL 2.5) according to the
random assignment. The treatments were continued with
fixed stimuli, making sure that the motor seizure duration
exceeded 25 s. If the generalized motor seizure was short-
er, the patient was restimulated after about 60 s with a
25% larger charge, and if no seizure occurred, restimula-
tion was given after about 30s.
Randomization
After assignment to Group 1 and Group 2, patients were
randomized by computer using a block randomization
(six patients per block) to RUL 5, RUL 2.5, and bifrontal
(BF) ECT in Group 1, and to RUL 5, and RUL 2.5 in Group
2. Assignment was concealed until administration of the
first ECT treatment. The comparison between RUL and BF
ECT has been reported separately.
Blinded clinical evaluations
All evaluators (the attending physicians and the raters)
and the patients were blinded to the assignment. The
number of treatments was determined by the attending
physician. The ECT treatment course was finished when a
patient 1) had two or less of the nine symptoms for DSM-
IV major depressive episode A criteria, or 2) no further im-
provement occurred after two consecutive treatments
based on change of the same criteria. The HDRS ratings
were carried out one to three days prior to the first ECT
treatment (pre-ECT HDRS), the day after the fourth treat-
ment (HDRS 4) and one to three days after the last rand-
omized ECT (post-ECT HDRS). The reliability ratings of
the three HDRS raters were evaluated by videotapes of the
depressed patients three times during the study. The
HDRS scores at these three occasions for the three raters
were as follows: first rating; 21, 18, 20, second rating; 23,
22, 21, and third rating; 20, 22, 20. In the case of a mark-
edly poor clinical improvement after eight treatments (de-
crease in HDRS score < 30% from baseline), the patient
received a course of conventional bitemporal (BT) ECT
treatment dosed at 150% above the BT seizure threshold
level. Psychiatric nurses assessed global cognitive status by
the standardized Mini-Mental State Examination (MMSE)
[11] prior to the first ECT (pre-ECT MMSE), the day after
the fourth treatment (MMSE 4), and one to three days af-
ter the last randomized ECT (post-ECT MMSE).
Medication
The patients were allowed to use either lorazepam (maxi-
mally ~3 mg/day) or chlorpromazine (maximally ~300
mg/day) for anxiety and chloral hydrate (maximally ~2 g)
at night during the study. The median (mean, range) dos-
es for lorazepam, chlorpromazine, and chloral hydrate
were as follows: 0.8, 1.1, 0–3.0; 19.2, 60.3, 0–320.3; 1.0,
1.0, 0–2.1. The median (range) lorazem dose in patients
treated with RUL 5 was smaller than in patients treated
with RUL 2.5 in Group 2 (0.6, 0–1.7 vs. 1.6, 0–3.0, P =
0.020, Mann-Whitney U test). There were no other statis-
tically significant differences (p > 0.05) in the doses of
psychotropic medications between the ECT groups or any
difference between depression groups.
Table 1: Clinical characteristics of the ITT sample (n = 40)
Whole Group mean ± 
SD
Group 1(n = 16) mean ± 
SD
Group 2 (n = 24) mean ± 
SD
P
Age (years) 53.0 ± 11.0 57.1 ± 10.4 50.3 ± 10.7 ns
Sex (female/male) 25/15 10/6 15/9 ns
Previous ECT (yes/no) 12/28 6/10 6/18 ns
Unipolar/bipolar depression (yes/no) 34/6 13/3 21/3 ns
Duration of current episode (wk)a 54.3 ± 34.5 47.8 ± 34.3 58.6 ± 34.6 ns
Pre-ECT HDRS score 25.3 ± 6.8 28.6 ± 5.4 23.0 ± 6.9 0.0093
Psychotic features (DSM-IV)(yes/no) 5/35 3/13 2/22 ns
Pre-ECT MMSE score 27.2 ± 2.3 26.0 ± 2.6 28.1 ± 1.6 0.0053
Number of antidepressant trials during episode 2.2 ± 1.4 1.9 ± 1.2 2.3 ± 1.5 ns
Prior adequate antidepressant treatment (yes/no) 34/6 14/2 20/4 ns
Fisher's Exact Test is used for nominal variables and independent sample t-test or Mann-Whitney U test (for non-normal distributions) for continu-
ous variables. a An upper limit of 104 weeks was used.BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/2
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Primary outcome measures
The HDRS and MMSE scores prior to ECT treatment were
used as the baseline values, and the percentage of change
by the randomized treatments was calculated after the last
treatment. The patients were considered to have respond-
ed to treatment if the improvement in HDRS score was at
least 60% and they had a total score of less than ten. Our
second primary outcome measure was the number of ECT
treatments given. We used an estimate for the number of
treatments for those patients who had markedly poor re-
sponse (decrease in HDRS score < 30% from baseline) to
eight randomized ECT treatments and were therefore
treated with the BT ECT. This estimate was 14 because de-
termined on a clinical basis, the maximal number of the
randomized treatments was 13. The patients were consid-
ered to have a cognitive risk if they had any worsening in
the MMSE total score. The possibility for the concomitant
occurrence of cognitive risk and clinical non-response was
calculated for all patients.
Statistical methods
Analyses were performed from the intent-to-treat (ITT)
sample using the last-observation-carried-forward
(LOCF) method. For this analysis, we included both study
completers and non-completers who had received at least
one ECT treatment after randomization. For five patients,
post-ECT HDRS scores were not available. For these pa-
tients, the HDRS ratings and number of randomized treat-
ments were as follows: HDRS 4, six; HDRS 4, eight; HDRS
4, twelve; pre-ECT HDRS, one; pre-ECT HDRS, three. Re-
garding MMSE analysis, pre-ECT MMSE scores were not
available for four patients. For three patients post-ECT
MMSE scores were not available. The MMSE ratings and
number of randomized treatments for these three patients
were as follows: MMSE 4, eight; pre-ECT MMSE, three;
MMSE 4, seven. As a sensitivity analysis, we also per-
formed an analysis among study completers who had
HDRS and MMSE ratings both prior and after the course
of the randomized treatment.
Fisher's Exact Test was used to compare the proportions of
different characteristics between the groups. For compari-
Table 2: ECT parameters of the ITT sample
Whole Group Group 1 Group 2 P
mean ± SD mean ± SD mean ± SD
Initial seizure threshold (mC) 52.3 ± 14.4 55.1 ± 13.7 50.4 ± 14.9 ns
RUL 5 / RUL 2.5 20/20 8/8 12/12 ns
Charge (mC) 208.0 ± 88.1 218.5 ± 82.3 200.6 ± 93.0 ns
Duration of seizures, motor (s) 42.8 ± 6.3 41.1 ± 5.3 43.9 ± 6.8 ns
Duration of seizures, EEG (s) 53.3 ± 17.6 54.8 ± 24.9 52.3 ± 10.7 ns
Fisher's Exact Test is used for nominal variables and independent sample t-test or Mann-Whitney U test (for non-normal distributions) for continu-
ous variables. All parameters except those for the initial seizure threshold refer to mean ± SD values after the first treatment. mC, millicoulombs.
Table 3: Clinical outcome of the ITT sample by depression groups
Whole Group Group 1 Group 2 P
Mean ± SD Mean ± SD Mean ± SD
HDRS change (%) 45.6 ± 26.0 64.3 ± 18.7 33.1 ± 22.7 <0.0001d
Responders (yes/no)a 12/28 10/6 2/22 0.0004
No. of treatments 7.7 ± 3.2 8.3 ± 2.5 7.4 ± 3.5 ns
MMSE change (%)b -1.8 ± -10.1 2.7 ± 11.2 -5.3 ± -7.6 0.0159e
Cognitive risk (yes/no)c 18/18 6/10 12/8 ns
Cognitive risk and nonresponse (yes/no) 11/25 1/15 10/10 0.0091
Fisher's Exact Test is used for nominal variables and independent sample t-test or Mann-Whitney U test (for non-normal distributions) for continu-
ous variables. aResponse = HDRS change (%)≥  60, and post-ECT HDRS score < 10. bPositive values on percentage change indicate a better cogni-
tive functioning as compared with baseline. cCognitive risk = MMSE change < 0%. dP = 0.0036 using ANCOVA with pre-ECT HDRS score and age 
as covariates. eP = 0.1803 using ANCOVA with pre-ECT MMSE score and age as covariates.BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/2
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son of means independent sample t-test was used. For
non-normal distributions, the comparisons were done
with Mann-Whitney's U test. Normality was evaluated
with the Shapiro-Wilk-test. The outcome measures were
adjusted for the initial group differences by Analysis of co-
variance (ANCOVA). ANCOVA was not used for the
number of treatments because this measure was not nor-
mally distributed. All tests were two-tailed, and the statis-
tical significance level was set to α  = 0.05. Statistical
computations were performed with the BMDP New Sys-
tem [BMDP Statistical, Software, Inc, Los Angeles, Califor-
nia, 1994] except for the ANCOVA which was done with
the SPSS for Windows 10.0 (SPSS Inc., Chicago, USA).
Results
Attrition
Six out of 40 patients (15%), one in Group 1 (6%) and
five in Group 2 (21%) were non-completers. In Group 1,
one RUL 2.5 patient had to discontinue the treatment af-
ter seven ECT treatments because of ventricular extrasysto-
lia. In Group 2, one RUL 5 patient had to discontinue the
course of the treatment after three treatments because of
regurgitation of gastric contents, one RUL 2.5 patient after
the first treatment because of a hypomanic switch, two
RUL 5 patients after three treatments because of high ele-
vations of blood-pressure, and one RUL 2.5 patient after
three treatments due to alcohol abuse. The decision to dis-
continue ECT treatment was made by the patient in one
case, by the anesthetist in four cases, and by the attending
physician in one case.
Baseline characteristics
The Group 1 patients tended to be older (t = 1.99, df = 38,
P = 0.0539), had higher baseline HDRS scores (t = 2.74, df
= 38, P = 0.0093), and lower baseline MMSE scores (P =
0.0053, Mann-Whitney U test) than Group 2 patients (Ta-
ble 1). The mean (SD) age (years) of the RUL 5 patients
was higher than that of the RUL 2.5 patients in Group 2
(55.3 ± 10.6 vs. 45.2 ± 8.5, t =2.59, df = 22, P = 0.017).
There were no other statistically significant differences be-
tween the depression groups or between the RUL ECT
groups.
Outcome of the treatment
Group 1 vs. Group 2
The number of responders vs. nonresponders was higher
in Group 1 than in Group 2 both in the ITT analysis (10/
6 vs. 2/22, P = 0.0004, Table 3) and among study compl-
eters (10/5 vs. 2/14, P = 0.0032).
The improvement in HDRS score was higher in Group 1
than in Group 2 both in the ITT analysis and among study
completers (64.3% vs. 33.1%, t =4.56, df = 38, P = 0.0001;
64.6% vs. 35.9%, t = 3.71, df = 29, P = 0.0009, respective-
ly). Using ANCOVA with pre-ECT HDRS scores as a cov-
ariate, the difference was statistically significantly
different in the ITT sample (P = 0.0016), and among study
completers (P = 0.0076), and remained statistically signif-
icantly different when both the pre-ECT HDRS scores and
age were used as covariates both in the ITT sample (P =
0.0036, Table 3), and among study completers (P =
0.0152).
Three patients received a course of BT treatment due to a
markedly poor response to randomized RUL ECT treat-
ment. The number of BT patients was not statistically sig-
nificantly different between Group 1 and Group 2 (1/15
vs. 2/22, P = 1.0).
The number of treatments was not different between
Group 1 and Group 2 in the ITT sample (Table 3) or
among study completers (median, mean, range: 8.0, 8.3,
4–14 vs. 8.0, 8.8, 4–14, P = 0.5844).
The mean MMSE scores improved in the Group 1 patients
in contrast to impairment in the Group 2 patients both in
the ITT sample and among the study-completers (2.7% vs.
-5.3%, t = -2.53, df = 34, P = 0.0159; 2.6% vs. -6.9%, t = -
2.52, df = 27, P = 0.0178, respectively). Using ANCOVA
with pre-ECT MMSE scores as a covariate, the difference
did not remain statistically different in the ITT sample (P
= 0.2518), and among study completers (P = 0.2333). The
difference was non-significant also with pre-ECT MMSE
scores and age as covariates in the ITT sample (P = 0.1803,
Table 3), and among study completers (P = 0.0961).
The likelihood of the occurrence of a simultaneous cogni-
tive risk and non-response was significantly higher for
Group 2 than for Group 1 in the ITT sample (10/10 vs. 1/
15, P = 0.0091, Table 3) and among the study completers
(8/6 vs. 1/14, P = 0.0052).
The ten patients in Group 2 who had simultaneous cogni-
tive risk and non-response were included in Group 2 be-
cause of their mild major depressive episode (n = 4),
because of their history of previous non-affective psycho-
sis (n = 2), because of alcohol abuse (n = 2), and because
of severe medical illness (n = 2). Nine of them had had ad-
equate antidepressant treatments during the current ma-
jor depressive episode.
RUL 5 vs. RUL 2.5
In the ITT sample, there were no statistically significant
differences in primary outcome measures between the
RUL ECT treatments in Group 1 or Group 2. The median
(mean, range) number of treatments of RUL 5 patients
tended to be smaller than that of RUL 2.5 patients in
Group 1 (7.0, 7.3, 4–12 vs. 8.0, 9.3, 7–14, P = 0.0503).
Among study completers, the difference was statistically
significant in Group 1 (7.0, 7.3, 4–12 vs. 8.0, 9.6, 7–14, PBMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/2
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= 0.0321), but not in Group 2 (8.0, 8.1, 4–12 vs. 8.0, 9.5,
6–14, P = 0.5886).
Treatment characteristics
There was no difference in ECT parameters between the
depression groups (Table 2). The median (mean, range)
RUL 5 dose (mC) was higher than the RUL 2.5 dose both
in Group 1 and Group 2 (252.0, 277.7, 252.0–378.0 vs.
126.0, 159.3, 75.6–252.0, P = 0.0014; 252.0, 268.0,
126.0–378.0 vs. 126.0, 127.1, 75.6–201.6, P = 0.0001,
Mann-Whitney U test, respectively). No other differences
were found between the RUL ECT groups.
Discussion
This study shows that patients with low severity of a major
depressive episode or with a variety of somatic or psychi-
atric comorbidities have a significantly lower response
rate to RUL ECT (8%) than patients with a pure, moderate
to severe major depressive episode (63%). The abysmal
response rate in Group 2 is based upon quite strict re-
sponse criteria, i.e., a decrease of at least 60% in HDRS
scores from baseline and a post-ECT score less than ten.
For comparison, the mean percentage improvement in
HDRS was 33% in Group 2 as compared with 64% in
Group 1. This difference is also both clinically and statis-
tically significant.
Why did the patients in our two depression groups have
such different antidepressant responses to the RUL ECT? A
long duration of a current depressive episode, and failure
to respond to one or more adequate medication trials
have been shown to predict a diminished rate of ECT re-
sponse [12]. In our study, there were no differences be-
tween these variables in the depression groups (Table 1).
Furthermore, when patients take benzodiazepines during
a course of unilateral ECT, the maximum therapeutic re-
sponse may be compromised [13]. The mean dose of lo-
razepam (1.1 mg/d) of our patients was at the same level
as in the previous efficacy studies (1.0 mg/d, and 1.2 mg/
d) [5,14]. In our study, the mean dose of lorazepam was
not different between the depression groups. Findings re-
garding the effects of age on short-term efficacy of ECT
have been somewhat inconsistent. Some studies have re-
ported that advancing age can be used to predict good re-
sponse to ECT [15,16] while other studies have not found
this relationship [17]. Thus, the higher mean age of our
Group 1 patients (Table 1) may have had some beneficial
effect on their treatment outcome as compared to Group
2 patients, but on the other hand, the lower mean age in
Group 2 may reflect a greater burden of co-morbidity
leading to earlier referral for ECT. The patients in Group 2
had less severe depression than those in Group 1. None of
our patients who were included in the analysis in Group
2 because of a mild major depression responded to the
ECT treatment. This finding is in agreement with that of
Hamilton and White [18] and questions, in general, the
usefulness of RUL ECT in patients with a major depression
of low severity. Many of our patients in Group 2 had sec-
ondary major depression, i.e. a depression occurring in a
person who has a preexisting non-affective psychiatric dis-
order (which may or may not still be present), or a serious
or life-threatening medical illness, which precedes and
parallels the symptoms of depression [19,20]. It has been
shown that patients with secondary depression are less
likely to recover from the index depressive episode [21]
and are more likely to receive inadequate treatment [22]
than patients with primary major depression. Moreover,
patients with secondary depression have been found to
have a poorer response to ECT treatment than patients
with a primary depressive disorder [15,22–24]. Zorumski
et al. [24] found that patients with alcohol dependence
and secondary depression had a favorable response to
ECT. However, concurrent alcohol dependence diminish-
es the likelihood that depression will respond to treat-
ment [25]. The subgroups in our study were too small for
any statistical analyses but one may conclude that the lack
of ECT efficacy in Group 2 was due to the prevalence of
secondary depression in this group especially as the effect
of ECT was lower in Group 2 than in Group 1 also after
the adjustment for initial differences in severity of depres-
sion and age between the two groups.
The lack of statistically significant differences in primary
outcome measures between RUL 5 and RUL 2.5 may indi-
cate that those two RUL ECT doses are equally good. On
the other hand, it may be due to insufficient statistical
power especially in Group 1 whereas in Group 2, it may
also be due to the very low response rate. The difference in
the median number of treatments between RUL 5 and
RUL 2.5 (seven vs. eight) was statistically different among
study completers but non-significant in the ITT sample in
Group 1. No reliability ratings concerning determinations
of number of treatments were done in contrast to the
HDRS ratings. Furthermore, despite the lower mean lo-
razepam dose in RUL 5 patients as compared to RUL 2.5
patients in Group 2, the difference between number of
treatments was statistically nonsignificant. Thus, the rela-
tion between speed of response and dose of RUL ECT
stimulus can not be answered by this study. The number
of cardiovascular complications (one in Group 1, and two
in Group 2) was so low that conclusions regarding tolera-
bility between our RUL treatments cannot be drawn.
However, in the study of Mayur et al. [26] none of the car-
diac-healthy patients (n = 95) treated with seizure thresh-
old level RUL ECT (mean dose 68 mC) had any clinically
observable cardiac complications. On the other hand, pa-
tients with cardiac disease have been shown to have a sig-
nificantly higher rate of cardiac complications during ECT
than a comparison group without cardiac disease [27].BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/2
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Therefore, there is a need to further study cardiovascular
side-effects induced by suprathreshold RUL ECT.
Depression affects a range of cognitive functions [28]. In
our study, the global cognitive status before ECT treat-
ment was poorer in Group 1 than in Group 2. Pre-ECT
global cognitive impairment has been found to be a
strong predictor of the magnitude of retrograde amnesia
for autobiographical information [29]. After RUL ECT in
our study, the possibility for simultaneous worsening in
global cognitive status and nonresponse was significantly
higher (Table 3) for Group 2 patients (50%) than Group
1 patients (6%). The difference of pre-ECT global cogni-
tive status, and the difference of the occurrence of simul-
taneous cognitive risk and nonresponse between
depression Group 1 and Group 2 needs clearly future
studies using more sophisticated neuropsychological
tests. The MMSE is a superficial method for ascertaining
ECT's cognitive side effects. Therefore, until there are more
studies on depressive patients with co-morbidity, the risk/
benefit ratio has to be assessed individually in different
subgroups of patients with major depression.
Conclusions
The good response to RUL ECT of the patient group with
major depression without co-morbidity was not found in
a heterogeneous co-morbid patient group. Most of the pa-
tients in this group had secondary major depression. In
addition, patients with a low severity of major depression
have a high risk/benefit ratio. The differences in the out-
comes between the two different doses of RUL ECT were
not statistically significant in the ITT sample. More re-
search is needed to clarify the response to ECT treatment
in different subgroups of patients with major depressive
episodes.
Competing interests
None declared
Acknowledgements
This study was supported by a grant to Dr Heikman from the Foundation 
for Psychiatric Research.
References
1. American Psychiatric Association: The practice of electroconvul-
sive therapy: recommendations for treatment, training, and
privileging. American Psychiatric Press, Washington DC, 2000
2. American Psychiatric Association: The practice of electroconvul-
sive therapy: recommendations for treatment, training, and
privileging. American Psychiatric Press, Washington DC, 1990
3. Royal College of Psychiatrists: The ECT Handbook. The 2nd Re-
port of the Royal College of Psychiatrists' Special Commit-
tee on ECT. Council Report CR39. Gaskell, London, 1995
4. Mc Call WV, Reboussin DM, Weiner RD, Sackeim HA: Titrated
moderately suprathreshold vs fixed high-dose right unilater-
al electroconvulsive therapy. Arch Gen Psychiatry 2000, 57:438-
444
5. Sackeim HA, Prudic J, Devanand DP, Nobler MS, Lisanby SH, Peyser
S, Fitzsimons L, Moody BJ, Clark J: A prospective, randomized,
double blind comparison of bilateral and right unilateral
electroconvulsive therapy at different stimulus intensities.
Arch Gen Psychiatry 2000, 57:425-434
6. American Psychiatric Association: Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition, DSM-IV. American
Psychiatric Press, Washington DC, 1994
7. American Psychiatric Association: Practice guideline for the
treatment of patients with major depression (revision). Am J
Psychiatry Suppl 2000, 157:2-4
8. Hamilton M: Development of a rating scale for primary de-
pressive illness. Br J Soc Clin Psychol 1967, 6:278-296
9. d'Elia G, Perris C: Comparison of electroconvulsive therapy
with unilateral and bilateral stimulation. I. Seizure and post-
seizure electroencephalographic pattern. Acta Psychiatr Scand
Suppl 1970, 215:9-29
10. Sackeim HA, Decina P, Prohovnik I, Malitz S: Seizure threshold in
electroconvulsive therapy: effects of sex, age, electrode
placement, and number of treatments. Arch Gen Psychiatry 1987,
44:355-360
11. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A
practical method for grading the cognitive state of patients
for the clinician. J Psychiatr Res 1975, 12:189-198
12. Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens
S, Greenberg R, Rifas SL, Sackeim HA: Resistance to antidepres-
sant medications and short-term clinical response to ECT.
Am J Psychiatry 1996, 153:985-992
13. Pettinati HM, Stephens SM, Willis KM, Robin SE: Evidence for less
improvement in depression in patients taking benzodi-
azepines during unilateral ECT. Am J Psychiatry 1990, 147:1029-
1035
14. Sackeim HA, Prudic J, Devanand DP, Kiersky JE, Fitzsimons L, Moody
BJ, McElhiney MC, Coleman EA, Settembrino JM: Effects of stimu-
lus intensity and electrode placement on the efficacy and
cognitive effects of electroconvulsive therapy. N Engl J Med
1993, 328:839-846
15. Black DW, Winokur G, Nasrallah A: A multivariate analysis of
the experience of 423 depressive inpatients treated with
electroconvulsive therapy. Convuls ther 1993, 9:112-120
16. Tew Jr JD, Mulsant BH, Haskett RF, Prudic J, Thase ME, Crowe RR,
Dolata D, Begley AE, Reynolllds III CF, Sackeim HA: Acute efficacy
of ECT in the treatment of major depression in the old-old.
Am J Psychiatry 1999, 156:1865-1870
17. Brodaty H, Hickie I, Mason C, Prenter L: A prospective follow-up
study of ECT outcome in older depressed patients. J Affect Dis-
ord 2000, 60:101-111
18. Hamilton M, White JM: Factors related to the outcome of de-
pression treated with ECT. J Ment Sci 1960, 106:1031-1041
19. Feighner JP, Robind E, Guze SB, Woodruff RA, Winokur G, Munoz R:
Diagnostic criteria for use in psychiatric research. Arch Gen
Psychiatry 1972, 26:57-63
20. Spitzer RL, Endicott J, Robins E: Research diagnostic criteria. Arch
Gen Psychiatry 1978, 35:773-782
21. Coryell W, Zimmerman M, Pfohl B: Short-term prognosis in pri-
mary and secondary major depression.  J Affect Disord 1985,
9:265-270
22. Black DW, Winokur G, Nasrallah A: Treatment and outcome in
secondary depression: a naturalistic study of 1087 patients. J
Clin Psychiatry 1987, 48:438-441
23. Davidson J, Turnbull CD, Miller RD: A comparison of inpatients
with primary unipolar depression and depression secondary
to anxiety. Acta Psychiatr Scand 1980, 61:377-386
24. Zorumski CF, Rutherford JL, Burke WJ, Reich T: ECT in primary
and secondary depression. J Clin Psychiatry 1986, 47:298-300
25. Mueller TI, Lavori PW, Keller MB, Swartz A, Warshaw M, Hasin D,
Coryell W, Endicott J, Rice J, Akiskal H: Prognostic effect of the
variable course of alcoholism on the 10-year course of de-
pression. Am J Psychiatry 1994, 151:701-706
26. Mayur PM, Gangadhar BN, Girish K, Prasad KMK, Subbakrishna DK,
Janakiramiah N: Acute post-ECT cardiovascular response: A
comparison of threshold right unilateral and bilateral ECT. J
ECT 1998, 14:94-98
27. Zielinski RJ, Roose SP, Devanand DP, Woodring S, Sackeim HA: Car-
diovascular complications of ECT in depressed patients with
cardiac disease. Am J Psychiatry 1993, 150:904-909
28. Austin MP, Mitchell P, Goodwin GM: Cognitive deficits in depres-
sion: possible implications for functional neuropathology. Br J
Psychiatry 2001, 178:200-206BMC Psychiatry 2002, 2 http://www.biomedcentral.com/1471-244X/2/2
Page 8 of 8
(page number not for citation purposes)
29. Sobin C, Sackeim HA, Prudic J, Devanand DP, Moody BJ, McElhiney
MC: Predictors of retrograde amnesia following ECT. Am J Psychiatry
152:995-1001
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com